U.S. to Phase Out AIDS Funding for South Africa Over Policy Disputes

In a sweeping shift that threatens to upend the global fight against HIV, the United States is officially phasing out its support for South Africa through the President's Emergency Plan for AIDS Relief (PEPFAR). According to an unsigned statement from the State Department, the U.S. will begin a phased drawdown of funding for HIV prevention and treatment programs, effectively ending a decades-long partnership that has kept millions of South Africans alive.[1][7]

The decision stems from an executive order issued by President Donald Trump in February 2025, which accused the South African government of discriminating against white Afrikaners. The administration directed federal agencies to halt foreign aid unless Pretoria reversed specific land and affirmative action policies. U.S. officials maintain that South Africa was repeatedly warned that its PEPFAR funding was at risk if it failed to heed the administration's demands.[2]

South African officials have categorically rejected the U.S. claims, defending their affirmative action and land reform policies as essential tools for addressing the deep, structural inequalities left behind by apartheid. The diplomatic standoff has now spilled over into the public health sector, leaving South Africa—a country where an estimated 7.8 million people live with HIV—scrambling to fill a massive financial void.[2][5]

The scale of the U.S. withdrawal is staggering. In 2024, South Africa received approximately $456 million in PEPFAR funding, which historically covered about 18 percent of the nation's total HIV budget. While a temporary $115 million "Bridge Plan" was approved in late 2025 to prevent an immediate collapse, that funding window closed in March 2026, leaving the country's health sector largely on its own.[2][3]

The impact of the initial funding freezes has already been severe. According to the UNAIDS Global AIDS Update, the abrupt cuts in early 2025 caused viral load testing in South Africa to plummet by 21 percent within a single month. This critical loss of data severely undermined the government's ability to monitor treatment efficacy and track the virus's spread across vulnerable communities.[5]

On the ground, the withdrawal has devastated the network of non-governmental organizations (NGOs) and community-led groups that serve as the backbone of South Africa's HIV response. Without U.S. backing, many of these organizations were forced to halt vital outreach programs, suspend efforts to re-engage patients who had dropped out of care, and lay off specialized staff. Consequently, an estimated 85 percent of local health facilities have reported acute staff shortages.[5]

The crisis is compounded by broader shifts in international health financing. The Global Fund to Fight AIDS, Tuberculosis and Malaria—now the primary external supporter of South Africa's key population services—is also scaling back its contributions. The Fund is redirecting its resources toward poorer nations, arguing that middle-income countries like South Africa must accelerate their path to self-reliance and full domestic financing.[4]

To mitigate the fallout, the South African government has been forced to redirect hundreds of millions of rand from other critical social programs, including the National Revenue Fund, to keep clinics operational. Health experts warn that shifting this financial burden onto already overstretched provincial health systems risks catastrophic service gaps and delays in life-saving care.[5][6]

Geopolitics have further complicated the funding landscape. Beyond the domestic U.S. focus on South Africa's internal policies, parliamentary monitors in Pretoria have noted that South Africa's case against Israel at the International Court of Justice introduced an additional layer of friction. This diplomatic rift is widely viewed as a compounding factor that accelerated the punitive cuts to U.S. health assistance.[5]

Looking ahead, the phased drawdown aims for a complete termination of U.S. HIV support by early 2027. The funding collapse has already excluded South Africa from a U.S.-backed initiative to distribute lenacapavir, a revolutionary long-acting HIV prevention drug administered just twice a year. As external funding dries up, South Africa faces the monumental task of integrating its HIV financing into a proposed National Health Insurance system before the epidemic regains its deadly momentum.[2][3][6]